Publications by authors named "Y Hayata"
DNA aptamers have attracted attention as an alternative modality for biomolecules due to their excellent target binding specificity and thermal stability, and they are also expected to be applied as artificial agonists for receptor proteins. DNA aptamer agonist TD0 targeting the receptor of fibroblast growth factor (FGFR), which plays an important role in the fields of wound healing and regenerative medicine, has been reported to induce cellular responses as well as its native ligands. However, it was also noted that there were some different responses upon long-term stimulation, suggesting that the intracellular signals induced by DNA aptamer agonist TD0 are different from those of natural ligands.
View Article and Find Full Text PDFArticle Synopsis
- Proton beam therapy (PBT) is a potential treatment option for hepatocellular carcinoma (HCC), and this study aimed to compare its effectiveness with radiofrequency ablation (RFA) in treatment-naïve cases.
- The study involved 95 patients treated with PBT and 836 treated with RFA, focusing on their recurrence-free survival (RFS) and overall survival (OS) after matching similar patients.
- Results showed that while PBT had higher RFS rates at 1, 3, and 5 years compared to RFA, overall survival rates were similar, and PBT had fewer significant adverse events.
Objective: To investigate whether maintenance treatment could be safely and effectively performed with olaparib, olaparib plus bevacizumab and niraparib in platinum-sensitive advanced ovarian cancer at multiple institutions in Japan.
Methods: We investigated progression-free survival and adverse events in 117 patients with platinum-sensitive advanced ovarian cancer treated with maintenance therapy.
Results: The median progression-free survival of 117 patients was 20.
Background/aim: To determine if maintenance treatment can be performed effectively and safely in patients with platinum-sensitive relapsed ovarian cancer.
Patients And Methods: We carried out a multi-center study to investigate progression-free survival (PFS) and adverse events (AEs) in 229 patients receiving maintenance treatment for platinum-sensitive relapsed ovarian cancer.
Results: The median PFS in the 229 patients with maintenance treatment was 14.
BACKGROUND Anticardiolipin antibodies in patients with Libman-Sacks endocarditis (LS) are indicative of comorbid antiphospholipid syndrome (APS) and can result in cerebral infarctions. We describe a case of LS and primary APS with recurrent cerebral infarctions despite anticoagulation treatment. The patient underwent surgery for enlarged LS vegetation with high titers of antiphospholipid antibodies.
View Article and Find Full Text PDF